Cancer genomic profiling (CGP) test may reveal presumed germline pathogenic variant / germline pathogenic variant (PGPV/GPV). Therefore, patients should decide in advance whether or not they want to learn about their PGPV/GPVs. We report a case in which the patient changed the mind 7 months after the CGP test. A 67-year-old female patient with lung cancer underwent CGP testing because of disease progression after primary treatment with cytotoxic anti-cancer drugs. Although she initially did not want to learn her PGPVs and did not change her mind when she heard the results of the CGP test, she changed her mind and requested disclosure of PGPVs 7 months later. When she heard the result of CGP test, she was full of anxiety about her next treatment and complained of hyposomnia. Mental support by a professional nurse and follow-up by a by a cancer genome medical coordinator (CGMC) enabled her to discuss with her family how to deal with PGPVs. A confirmatory test verified the germline pathogenic variant. The patient's daughters were followed up at the genetic clinic. In this case, the collaboration among nurses, doctors, and the genetic medicine department coordinated by the CGMC strongly supported the patient's decision-making process. In this report, we present our approach in establishing collaboration among various healthcare professionals.